Desmoid Tumor Treatment Market By Treatment Type (Targeted Therapy, Active Surveillance and Minimally Invasive Procedures, Surgery, Chemotherapy and Other Systemic Treatments); By Diagnosis Type (Biopsy-Based Diagnosis, Immunohistochemical Analysis, Electron Microscopic Examination and Other Diagnostic Methods); By End User (Hospitals and Multispecialty Healthcare Systems, Specialty Sarcoma and Oncology Centers, Ambulatory and Outpatient Treatment Centers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

Targeted Drugs Open a New Growth Phase in Desmoid Tumor Care

The Global Desmoid Tumor Treatment Market was valued at USD 350 million in 2025 and is projected to reach USD 890 million by 2032, expanding at a CAGR of 14.25% during 2026–2032.

 

Desmoid Tumor Treatment Market covers therapies, procedures, and monitoring approaches used for managing desmoid tumors (aggressive fibromatosis), a rare type of soft-tissue tumor that does not metastasize but can cause significant local damage by invading surrounding tissues.

 

Desmoid tumors remain a rare disease, affecting approximately 2–6 people per million annually worldwide, with around 900–1,500 new cases diagnosed each year in the United States. Although incidence is low, treatment demand is increasing because many patients require long-term disease management. The estimated global patient pool includes approximately 150,000 diagnosed patients, of which nearly 22,000 require active treatment and around 9,000 are candidates for systemic therapy, creating a growing opportunity for targeted drug manufacturers.

 

The largest transformation within the market is driven by targeted therapy adoption, especially gamma-secretase inhibitors (GSIs) that interfere with the Notch signaling pathway involved in desmoid tumor growth. Nirogacestat (Ogsiveo), developed by SpringWorks Therapeutics, became the first FDA-approved systemic therapy specifically for adult patients with progressing desmoid tumors, creating a new commercial category within rare tumor treatment. The targeted therapy segment accounted for approximately 20% penetration among systemic therapy candidates in 2025 and is expected to expand rapidly as awareness and access improve.

 

The expanding pipeline of desmoid-specific therapies is further strengthening future market potential. AL102, developed by Immunome/Ayala Pharmaceuticals, is an investigational gamma-secretase inhibitor being evaluated for desmoid tumors, while tegavivint from Iterion Therapeutics is being studied for tumors associated with beta-catenin pathway activation, a key molecular feature observed in desmoid disease. These programs indicate increasing pharmaceutical focus on rare tumor biology and support the development of multiple treatment options beyond the first approved therapy.

 

Overall, the Desmoid Tumor Treatment Market is transitioning from invasive treatment models toward personalized, long-term disease control. Growth will be primarily influenced by wider adoption of gamma-secretase inhibitors, expansion of clinical pipelines, improved patient identification, and increasing recognition of desmoid tumors as a chronic condition requiring specialized therapeutic management rather than a one-time surgical intervention.

 

Precision Diagnostics and Rare Tumor Therapies Shift Revenue

By Treatment Type

Leading and Fastest-Growing Segment: Targeted Therapy — Revenue Growth Driven by First Disease-Specific Treatments

Targeted Therapy represents the leading segment in the Desmoid Tumor Treatment Market, contributing nearly 35% of total market revenue, valued at approximately USD 122.5 million in 2025, and is expected to grow at a CAGR of 22.0% from 2026 to 2032. This segment is gaining commercial importance as targeted agents enable disease control by selectively interfering with tumor-driving pathways, offering a more tolerable alternative to conventional systemic treatments for patients requiring active intervention.

Targeted therapy is becoming a central treatment approach in the Desmoid Tumor Treatment Market as clinicians increasingly adopt molecularly driven therapies that control tumor growth while reducing treatment-related burden. The growing use of agents targeting Wnt/β-catenin and Notch pathway activity, including gamma-secretase inhibitors and tyrosine kinase inhibitors, is expanding treatment options for patients with progressive or symptomatic desmoid tumors.

 

By Diagnosis Type

Leading Segment: Biopsy-Based Diagnosis — Foundation of Confirmatory Disease Detection

Biopsy-based diagnosis represents the leading diagnostic segment in the Desmoid Tumor Treatment Market, accounting for nearly 60% share, equivalent to approximately USD 210 million in 2025 revenue, and is projected to expand at a CAGR of 13.0% during 2026–2032. The segment remains central to desmoid tumor management as histopathological confirmation is essential for distinguishing aggressive fibromatosis from malignant sarcomas and other soft-tissue lesions. Increasing adoption of precision diagnostics, including core needle biopsy, beta-catenin immunohistochemistry, and CTNNB1 mutation analysis, is strengthening treatment decisions by enabling clinicians to select surveillance, targeted therapies, or systemic treatment approaches while reducing unnecessary surgical interventions.

Fastest-Growing Segment: Immunohistochemical Analysis — Supporting Molecular Treatment Decisions

Immunohistochemical (IHC) analysis represents the fastest-growing diagnostic segment in the Desmoid Tumor Treatment Market, accounting for approximately 25% of the market share, valued at USD 87.5 million in 2025, and is projected to expand at a CAGR of 15.5% during 2026–2032. The increasing adoption of IHC testing is linked to its critical role in confirming desmoid tumor diagnosis, identifying β-catenin expression patterns, and differentiating aggressive fibromatosis from other soft-tissue tumors. Accurate pathological classification enables clinicians to select appropriate management approaches, including surveillance, systemic therapy, or surgical intervention, supporting demand for advanced diagnostic solutions in desmoid tumor care.

 

By End User

Leading Segment: Hospitals and Multispecialty Healthcare Systems — Primary Treatment Hub

Hospitals account for the leading share of the Desmoid Tumor Treatment Market, capturing approximately 65% of total revenue, equivalent to USD 227.5 million in 2025, and are expected to expand at a CAGR of 12.5% during 2026–2032.

Hospitals remain the primary treatment centers for desmoid tumors due to their ability to provide multidisciplinary sarcoma care, advanced diagnostic capabilities, and access to evolving treatment options. Specialized hospital teams comprising surgeons, oncologists, radiologists, and pathologists evaluate tumor progression and determine personalized treatment strategies, including active surveillance, surgery, systemic therapies, radiation, and minimally invasive interventions. Growing adoption of MRI-based monitoring, targeted therapies, and image-guided procedures is further strengthening hospital revenue opportunities within the desmoid tumor treatment ecosystem.

Fastest-Growing Segment: Specialty Sarcoma and Oncology Centers — Expansion of Rare Tumor Expertise

Specialty sarcoma and oncology centers represent approximately 25% of the Desmoid Tumor Treatment Market, generating nearly USD 87.5 million in revenue in 2025, and are projected to record the fastest end-user growth with a CAGR of 17.0% during 2026–2032. These centers play a critical role in desmoid tumor management by providing multidisciplinary expertise for accurate diagnosis, molecular confirmation, treatment selection, and access to advanced therapies. Increasing referrals to specialized centers are supported by the need to differentiate desmoid tumors from aggressive malignancies, reduce unnecessary surgeries, and improve adoption of targeted therapies, cryoablation, and active surveillance approaches.

 

By Geography

Leading Region: North America — Strong Adoption of Innovative Therapies

North America dominates the Desmoid Tumor Treatment Market, accounting for approximately 45% of global revenue share, equivalent to USD 157.5 million in 2025. The regional market is projected to grow at a CAGR of 15.0% during 2026–2032, supported by wider use of systemic therapies for progressing, symptomatic, unresectable, and recurrent desmoid tumors. Treatment pathways are increasingly moving away from routine upfront surgery toward active surveillance for stable disease and pharmacological treatment for patients requiring intervention. This transition is expanding the addressable patient pool for desmoid-specific systemic therapies and reshaping treatment demand across oncology and specialty-care centers in North America.

Fastest-Growing Region: Asia-Pacific — Improving Diagnosis and Treatment Access Create New Opportunities

Asia-Pacific accounts for approximately 18% of the global Desmoid Tumor Treatment Market, generating around USD 63 million in revenue in 2025. The region is projected to expand at a CAGR of 16.5% from 2026 to 2032. Growth is increasingly linked to the expansion of specialist sarcoma care and wider use of systemic therapies for patients with progressing or symptomatic desmoid tumors. Greater clinical use of tyrosine kinase inhibitors, growing interest in gamma-secretase inhibitors, and participation of Asia-Pacific centers in desmoid tumor clinical research are widening the addressable treatment population. Japan, China, India, and other major healthcare markets are also expanding oncology and sarcoma referral networks, creating stronger access pathways for patients requiring long-term surveillance and systemic treatment.

 

New Pathway Drugs and Local Therapies Broaden Treatment Choice

Gamma-Secretase Inhibitors (GSIs): The First Disease-Specific Drug Class

Gamma-secretase inhibitors (GSIs) represent the most important advancement in desmoid tumor treatment because they directly target the Notch signaling pathway, which is involved in tumor cell proliferation.

Nirogacestat (Ogsiveo), developed by SpringWorks Therapeutics, became the first FDA-approved systemic therapy for adults with progressing desmoid tumors in 2023, establishing a new treatment category for patients who previously relied mainly on surgery, chemotherapy, or off-label therapies.

In the Phase 3 DeFi trial, nirogacestat demonstrated clinically meaningful improvements compared with placebo, with tumor shrinkage observed in approximately 40% of treated patients compared with 8% in the placebo group. The therapy also improved progression-free survival and patient-reported outcomes related to pain and physical functioning.

The commercial impact of GSIs is significant because approximately 9,000 patients globally are estimated to be eligible for systemic treatment, creating a concentrated but high-value target population for rare disease drug developers.

 

Varegacestat (AL102): Next-Generation Oral Gamma-Secretase Inhibitor

Varegacestat (formerly AL102), developed by Immunome following its acquisition of Ayala Pharmaceuticals, is an investigational once-daily oral gamma-secretase inhibitor designed to compete in the expanding targeted therapy market.

The Phase 3 RINGSIDE trial evaluated varegacestat in adults with progressing desmoid tumors. Reported clinical results showed significant improvements in progression control compared with placebo, supporting regulatory advancement.

If approved, varegacestat could expand treatment availability by providing an additional oral targeted option and increasing competition within the GSI category.

 

Beta-Catenin and Wnt Pathway Inhibitors: Targeting the Root Biology of Tumor Growth

Desmoid tumors are strongly associated with abnormalities in the Wnt/beta-catenin signaling pathway, making this pathway a major focus for next-generation drug development.

Tegavivint (BC2059), developed by Iterion Therapeutics, is an investigational therapy designed to inhibit beta-catenin activity, aiming to reduce tumor cell growth and survival. The therapy represents a different mechanism from GSIs and may provide options for patients who do not respond adequately to Notch pathway inhibition.

Other experimental approaches, including E7386 and additional Wnt pathway inhibitors, are being explored to expand treatment choices for this rare tumor population.

 

Cryoablation and Image-Guided Local Therapies: Minimally Invasive Disease Control

Percutaneous cryoablation is emerging as an alternative to surgery for selected patients, particularly those with localized tumors where complete surgical removal may cause functional damage.

The technique uses imaging guidance to freeze tumor tissue while reducing the need for major surgical procedures. Increasing adoption of minimally invasive interventions is supported by the shift toward preserving organ function and reducing recurrence-related complications.

 

Combination and Personalized Treatment Strategies

Future treatment approaches are expected to focus on combining systemic therapies with local interventions. Research is exploring combinations such as targeted therapies with cryoablation, biomarker-guided patient selection, and longer-term treatment strategies to maintain tumor control.

The increasing understanding of CTNNB1 mutations, Notch signaling, and tumor biology is enabling more personalized treatment decisions rather than a single standardized approach.

 

First-Approved Therapy Sets the Pace for Desmoid Drug Developers

SpringWorks Therapeutics — Commercial Leader with First FDA-Approved Desmoid Tumor Therapy

SpringWorks Therapeutics is currently the leading company in the desmoid tumor treatment market due to the commercialization of OGSIVEO (nirogacestat), the first FDA-approved systemic therapy specifically developed for adults with progressing desmoid tumors.

Nirogacestat is an oral gamma-secretase inhibitor (GSI) that blocks the Notch signaling pathway, a mechanism associated with desmoid tumor growth. The approval created a new pharmaceutical treatment category for patients who previously relied mainly on surgery, chemotherapy, or off-label therapies.

The Phase 3 DeFi clinical trial evaluated nirogacestat in 142 adult patients with progressing desmoid tumors and demonstrated a significant improvement in disease control compared with placebo. The trial reported an objective response rate of 41% in the nirogacestat group compared with 8% in the placebo group, supporting its role as a disease-specific treatment option.

The company is also expanding access through global regulatory efforts and continues evaluating broader applications of gamma-secretase inhibition across rare tumor indications.

Commercial role:

• Market creation through the first approved desmoid-specific drug.

• Establishes targeted therapy as the preferred systemic treatment approach.

• Captures the early high-value patient population requiring systemic therapy.

 

Immunome (Following Acquisition of Ayala Pharmaceuticals) — Advancing Next-Generation Gamma-Secretase Inhibitors

Immunome, through its integration of Ayala Pharmaceuticals’ pipeline, is developing varegacestat (AL102), an investigational oral gamma-secretase inhibitor designed to compete within the same therapeutic class as nirogacestat.

AL102 targets the Notch signaling pathway, aiming to provide another precision medicine option for patients with progressing desmoid tumors. The therapy has advanced through late-stage clinical development, including the Phase 3 RINGSIDE trial, which evaluated its ability to delay disease progression in adults with desmoid tumors.

The development of AL102 highlights increasing pharmaceutical investment in rare tumor markets where approved therapies remain limited and long-term disease management needs remain significant.

Commercial role:

• Builds competition within the gamma-secretase inhibitor category.

• Expands treatment options beyond the first approved therapy.

• Supports market growth through increased physician adoption of targeted medicines.

 

Iterion Therapeutics — Developing Wnt/Beta-Catenin Pathway-Based Treatment Approaches

Iterion Therapeutics is developing tegavivint (BC2059), a first-in-class investigational therapy targeting the Wnt/β-catenin signaling pathway, one of the key biological pathways involved in desmoid tumor development.

Unlike gamma-secretase inhibitors that target Notch signaling, tegavivint focuses on disrupting beta-catenin activity by targeting the TBL1/β-catenin transcriptional complex. This approach aims to inhibit tumor cell proliferation through a different molecular mechanism.

Clinical research has evaluated tegavivint in desmoid tumors and other Wnt-driven cancers, with early studies showing antitumor activity and manageable safety profiles.

Commercial role:

• Expands the pipeline beyond Notch pathway inhibition.

• Provides potential treatment alternatives for patients with inadequate response to GSIs.

• Strengthens future precision oncology opportunities in rare tumors.

 

Additional Oncology Developers Extend the Desmoid Pipeline

• Eisai / PRISM BioLab – Exploring targeted oncology approaches, including protein-protein interaction inhibitors that may address pathways involved in tumor progression.

• Bristol Myers Squibb – Participating in broader oncology innovation and rare tumor therapeutic research.

• Ipsen – Active in oncology and rare disease treatment areas, with potential relevance through its soft tissue tumor expertise.

• Deciphera Pharmaceuticals – Developing kinase-focused oncology therapies that contribute to the broader rare sarcoma treatment ecosystem.

• Zentalis Pharmaceuticals – Investigating pathway-based cancer therapies that may support future rare tumor treatment strategies.

 

Analyst View: Durable Control Reshapes Long-Term Care

The desmoid tumor treatment market is transitioning from surgery-focused management toward precision-based therapies and long-term disease control strategies. Growing adoption of active surveillance, gamma-secretase inhibitors such as nirogacestat, and emerging pathway-specific therapies targeting Notch and Wnt/β-catenin signaling is reshaping treatment decisions for progressing tumors. The next phase of market growth will be driven by therapies that provide durable tumor control with reduced functional complications, particularly for patients requiring systemic treatment.

 

Desmoid Tumor Treatment Market Report Coverage at a Glance

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 350 Million
Revenue Forecast in 2032	USD 890 Million
Overall Growth Rate	CAGR of 14.25% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026–2032)
Segmentation	By Treatment Type, By Diagnosis Type, By End User, By Geography
By Treatment Type	Targeted Therapy, Active Surveillance and Minimally Invasive Procedures, Surgery, Chemotherapy and Other Systemic Treatments
By Diagnosis Type	Biopsy-Based Diagnosis, Immunohistochemical Analysis, Electron Microscopic Examination and Other Diagnostic Methods
By End User	Hospitals and Multispecialty Healthcare Systems, Specialty Sarcoma and Oncology Centers, Ambulatory and Outpatient Treatment Centers
By Geography	North America, Europe, Asia-Pacific, Latin America and Middle East & Africa
Country Scope	U.S., Canada, Germany, France, Netherlands, China, India, South Korea, Japan, Brazil, Mexico, UAE, Saudi Arabia, South Africa
Market Drivers	wider adoption of gamma-secretase inhibitors, expansion of clinical pipelines, improved patient identification, and increasing recognition of desmoid tumors as a chronic condition
Customization Option	Available upon request